Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain

Chimeric antigen receptor (CAR) T-cell therapies directed against B-cell maturation antigen (BCMA) have shown compelling clinical activity and manageable safety in subjects with relapsed and refractory multiple myeloma (RRMM). Prior reported CAR T cells have mostly used antibody fragments such as hu...

Descripción completa

Detalles Bibliográficos
Autores principales: Buonato, Janine M., Edwards, Justin P., Zaritskaya, Liubov, Witter, Alexandra R., Gupta, Ankit, LaFleur, David W., Tice, David A., Richman, Laura K., Hilbert, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377753/
https://www.ncbi.nlm.nih.gov/pubmed/35737298
http://dx.doi.org/10.1158/1535-7163.MCT-21-0552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377753/
https://www.ncbi.nlm.nih.gov/pubmed/35737298
http://dx.doi.org/10.1158/1535-7163.MCT-21-0552

Ejemplares similares